Carisma Therapeutics Stock Forward View
| CARM Stock | 0.04 0 10.00% |
Carisma Stock outlook is based on your current time horizon. Although Carisma Therapeutics' naive historical forecasting may sometimes provide an important future outlook for the firm, we recommend always cross-verifying it against solid analysis of Carisma Therapeutics' systematic risk associated with finding meaningful patterns of Carisma Therapeutics fundamentals over time.
As of now, the RSI of Carisma Therapeutics' share price is approaching 44 suggesting that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Carisma Therapeutics, making its price go up or down. Momentum 44
Sell Extended
Oversold | Overbought |
EPS Estimate Next Quarter (0.12) | EPS Estimate Current Year (0.69) | EPS Estimate Next Year (0.52) | Wall Street Target Price 1 | Quarterly Revenue Growth 12.368 |
Using Carisma Therapeutics hype-based prediction, you can estimate the value of Carisma Therapeutics from the perspective of Carisma Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
Carisma Relative Strength Index
The Naive Prediction forecasted value of Carisma Therapeutics on the next trading day is expected to be 0.03 with a mean absolute deviation of 0 and the sum of the absolute errors of 0.20.Carisma Therapeutics Hype to Price Pattern
Investor biases related to Carisma Therapeutics' public news can be used to forecast risks associated with an investment in Carisma. The trend in average sentiment can be used to explain how an investor holding Carisma can time the market purely based on public headlines and social activities around Carisma Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Carisma Therapeutics' market sentiment to its price can help taders to make decisions based on the overall investors consensus about Carisma Therapeutics.
The Naive Prediction forecasted value of Carisma Therapeutics on the next trading day is expected to be 0.03 with a mean absolute deviation of 0 and the sum of the absolute errors of 0.20. Carisma Therapeutics after-hype prediction price | USD 0.04 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of Carisma Therapeutics to cross-verify your projections. Carisma Therapeutics Additional Predictive Modules
Most predictive techniques to examine Carisma price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Carisma using various technical indicators. When you analyze Carisma charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Carisma Therapeutics Cash Forecast
Forecasting financial indicators like cash flow involves analysts applying various statistical methods, techniques, and algorithms. These tools reveal hidden trends within the Carisma Therapeutics' financial statements to estimate their effects on upcoming price movements.
Cash | First Reported 2012-12-31 | Previous Quarter 2 M | Current Value 2.8 M | Quarterly Volatility 41.6 M |
Carisma Therapeutics Naive Prediction Price Forecast For the 31st of January
Given 90 days horizon, the Naive Prediction forecasted value of Carisma Therapeutics on the next trading day is expected to be 0.03 with a mean absolute deviation of 0, mean absolute percentage error of 0.000021, and the sum of the absolute errors of 0.20.Please note that although there have been many attempts to predict Carisma Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Carisma Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Carisma Therapeutics Stock Forecast Pattern
| Backtest Carisma Therapeutics | Carisma Therapeutics Price Prediction | Buy or Sell Advice |
Carisma Therapeutics Forecasted Value
In the context of forecasting Carisma Therapeutics' Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Carisma Therapeutics' downside and upside margins for the forecasting period are 0.0004 and 10.72, respectively. We have considered Carisma Therapeutics' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Carisma Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Carisma Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 107.3563 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.0032 |
| MAPE | Mean absolute percentage error | 0.0653 |
| SAE | Sum of the absolute errors | 0.1959 |
Predictive Modules for Carisma Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Carisma Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Carisma Therapeutics After-Hype Price Density Analysis
As far as predicting the price of Carisma Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Carisma Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Carisma Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Carisma Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Carisma Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Carisma Therapeutics' historical news coverage. Carisma Therapeutics' after-hype downside and upside margins for the prediction period are 0.00 and 10.65, respectively. We have considered Carisma Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Carisma Therapeutics is out of control at this time. Analysis and calculation of next after-hype price of Carisma Therapeutics is based on 3 months time horizon.
Carisma Therapeutics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Carisma Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Carisma Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Carisma Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.01 | 10.69 | 0.00 | 0.00 | 5 Events / Month | 6 Events / Month | In about 5 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.04 | 0.04 | 11.11 |
|
Carisma Therapeutics Hype Timeline
Carisma Therapeutics is currently traded for 0.04. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Carisma is projected to increase in value after the next headline, with the price projected to jump to 0.04 or above. The average volatility of media hype impact on the company the price is over 100%. The price boost on the next news is projected to be 11.11%, whereas the daily expected return is currently at 0.01%. The volatility of related hype on Carisma Therapeutics is about 6478.79%, with the expected price after the next announcement by competition of 0.04. Carisma Therapeutics currently holds 2.48 M in liabilities. Note, when we think about Carisma Therapeutics' use of debt, we should always consider it together with its cash and equity.Given the investment horizon of 90 days the next projected press release will be in about 5 days. Check out Historical Fundamental Analysis of Carisma Therapeutics to cross-verify your projections.Carisma Therapeutics Related Hype Analysis
Having access to credible news sources related to Carisma Therapeutics' direct competition is more important than ever and may enhance your ability to predict Carisma Therapeutics' future price movements. Getting to know how Carisma Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Carisma Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| JSPR | Jasper Therapeutics | (0.56) | 11 per month | 0.00 | (0.1) | 7.73 | (9.04) | 31.75 | |
| ONCO | Onconetix | (0.40) | 5 per month | 0.00 | (0.17) | 9.09 | (12.46) | 36.81 | |
| ENVB | Enveric Biosciences | 0.21 | 9 per month | 0.00 | (0.04) | 14.08 | (16.57) | 121.83 | |
| SPRC | Scisparc | (0.19) | 8 per month | 0.00 | (0.42) | 3.57 | (12.20) | 30.69 | |
| SLXN | Biomotion Sciences Ordinary | (0.04) | 5 per month | 0.00 | (0.10) | 15.09 | (8.19) | 37.24 | |
| SLRX | Salarius Pharmaceuticals | (0.02) | 6 per month | 0.00 | (0.19) | 16.00 | (16.92) | 61.05 | |
| REVB | Revelation Biosciences | (0.12) | 11 per month | 0.00 | (0.26) | 5.56 | (9.09) | 35.57 | |
| CDT | Conduit Pharmaceuticals | 0.01 | 10 per month | 0.00 | (0.22) | 10.06 | (11.97) | 32.20 | |
| INDP | Indaptus Therapeutics | 0.01 | 6 per month | 0.00 | (0.06) | 13.58 | (12.56) | 51.64 | |
| ASBP | Aspire BioPharma | (0.55) | 6 per month | 0.00 | (0.24) | 19.52 | (23.85) | 63.79 |
Other Forecasting Options for Carisma Therapeutics
For every potential investor in Carisma, whether a beginner or expert, Carisma Therapeutics' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Carisma Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Carisma. Basic forecasting techniques help filter out the noise by identifying Carisma Therapeutics' price trends.Carisma Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Carisma Therapeutics stock to make a market-neutral strategy. Peer analysis of Carisma Therapeutics could also be used in its relative valuation, which is a method of valuing Carisma Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Carisma Therapeutics Market Strength Events
Market strength indicators help investors to evaluate how Carisma Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Carisma Therapeutics shares will generate the highest return on investment. By undertsting and applying Carisma Therapeutics stock market strength indicators, traders can identify Carisma Therapeutics entry and exit signals to maximize returns.
Carisma Therapeutics Risk Indicators
The analysis of Carisma Therapeutics' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Carisma Therapeutics' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting carisma stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 8.52 | |||
| Semi Deviation | 9.17 | |||
| Standard Deviation | 11.6 | |||
| Variance | 134.67 | |||
| Downside Variance | 116.03 | |||
| Semi Variance | 84.06 | |||
| Expected Short fall | (10.64) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Carisma Therapeutics
The number of cover stories for Carisma Therapeutics depends on current market conditions and Carisma Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Carisma Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Carisma Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Carisma Therapeutics Short Properties
Carisma Therapeutics' future price predictability will typically decrease when Carisma Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Carisma Therapeutics often depends not only on the future outlook of the potential Carisma Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Carisma Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 41.5 M | |
| Cash And Short Term Investments | 18.8 M |
Check out Historical Fundamental Analysis of Carisma Therapeutics to cross-verify your projections. To learn how to invest in Carisma Stock, please use our How to Invest in Carisma Therapeutics guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Will Biotechnology sector continue expanding? Could Carisma diversify its offerings? Factors like these will boost the valuation of Carisma Therapeutics. Projected growth potential of Carisma fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Carisma Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share 0.19 | Revenue Per Share | Quarterly Revenue Growth 12.368 | Return On Assets | Return On Equity |
Understanding Carisma Therapeutics requires distinguishing between market price and book value, where the latter reflects Carisma's accounting equity. The concept of intrinsic value—what Carisma Therapeutics' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Carisma Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Carisma Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Carisma Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Carisma Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.